Apellis Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Apellis Pharmaceuticals announces its annual meeting of stockholders to be held virtually on June 3, 2025, covering director elections, auditor ratification, and executive compensation votes.
NASDAQ
Apellis Pharmaceuticals outlines its strategic achievements in 2024 and plans for 2025, focusing on expanding the market reach of EMPAVELI and SYFOVRE and advancing its pipeline.
NASDAQ
Apellis Pharmaceuticals will hold its annual stockholders meeting on June 5, 2024, to elect directors, ratify the appointment of its auditor, and conduct an advisory vote on executive compensation.
NASDAQ
Apellis Pharmaceuticals sets date for its 2024 annual stockholders meeting, outlining key proposals including director elections, auditor ratification, and executive compensation advisory vote.